Literature DB >> 6589029

Subacute and chronic myelomonocytic leukemia in children (juvenile CML). Clinical and hematologic observations, and identification of prognostic factors.

H Castro-Malaspina, G Schaison, S Passe, A Pasquier, R Berger, C Bayle-Weisgerber, D Miller, M Seligmann, J Bernard.   

Abstract

The clinical and hematologic characteristics of 38 children with subacute and chronic myelomonocytic leukemia (S & CMMOL) are described, and the prognostic significance of these characteristics as recorded at diagnosis is reported. The common and distinctive feature of these children was the excessive proliferation of cells of neutrophilic and monocytic series. The disease predominated in younger children, 95% were younger than 4 years, and boys were more affected than girls (22/16). The onset of the disease was heralded most often by acute or subacute symptoms. Splenomegaly was the most common physical finding at diagnosis. Leukocytosis was usually under 100 X 10(9)/l. Monocytosis and granulocytosis were often associated with normoblastosis, and, in some cases, with moderate blastosis (less than or equal to 30%). Severe anemia and marked thrombocytopenia were found in about one third of patients, increased fetal hemoglobin levels in 53%, and increased gamma-globulin levels in 50% of cases. The Philadelphia chromosome was absent in all blood and marrow cell karyotypes. Thirty-three of 38 patients were treated with moderate or intensive chemotherapy, and in all cases treatment never resulted in a complete remission. Terminal acute leukemia occurred in 11 cases. Of the 38 patients, 29 have died (median survival time, 16 months). Initial characteristics predicting a short survival (log-rank test) included: older age (greater than or equal to 2 years) (P less than 0.001), hepatomegaly (P less than 0.05), bleeding (P less than 0.001), thrombocytopenia (P less than 0.01), high counts of blasts and normoblasts in peripheral blood (P less than 0.01, P less than 0.01). Sex, infections, cutaneous manifestations, lymphadenopathy, degree of splenomegaly, hemoglobin levels, fetal hemoglobin, leukocyte counts, percent of blasts in bone marrow, and serum gamma-globulin levels were of no prognostic value. When survival was plotted on a semilogarithmic scale, a change in death rate was evident at the second year of survival suggesting that there may be two subgroups of patients with myelomonocytic picture, one with very rapid, and another with a slower rate of mortality. A stepwise discriminant-function analysis was performed in an attempt to distinguish between those children who lived less than or equal to 2 years and those who lived longer. A linear combination of variables which best discriminated between these two subgroups was found. Nearly all patients could be classified as a short-survivor or long-survivor on the basis of age and platelet, blast, and normoblast counts in peripheral blood.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6589029     DOI: 10.1002/1097-0142(1984)54:4<675::aid-cncr2820540415>3.0.co;2-q

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

1.  Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.

Authors:  Elliot Stieglitz; Camille B Troup; Laura C Gelston; John Haliburton; Eric D Chow; Kristie B Yu; Jon Akutagawa; Amaro N Taylor-Weiner; Y Lucy Liu; Yong-Dong Wang; Kyle Beckman; Peter D Emanuel; Benjamin S Braun; Adam Abate; Robert B Gerbing; Todd A Alonzo; Mignon L Loh
Journal:  Blood       Date:  2014-11-13       Impact factor: 22.113

2.  Cytogenetics investigation in childhood chronic myeloid leukemia.

Authors:  D Chinnappan; I C Verma; V P Choudhry; L S Arya
Journal:  Indian J Pediatr       Date:  2000-02       Impact factor: 1.967

3.  Juvenile myelomonocytic leukemia due to a germline CBL Y371C mutation: 35-year follow-up of a large family.

Authors:  Anand Pathak; Alexander Pemov; Mary L McMaster; Ramita Dewan; Sarangan Ravichandran; Evgenia Pak; Amalia Dutra; Hyo Jung Lee; Aurelie Vogt; Xijun Zhang; Meredith Yeager; Stacie Anderson; Martha Kirby; Neil Caporaso; Mark H Greene; Lynn R Goldin; Douglas R Stewart
Journal:  Hum Genet       Date:  2015-05-05       Impact factor: 4.132

Review 4.  Interferon-alpha in childhood haematological malignancies.

Authors:  R Simkó; K Nagy
Journal:  Postgrad Med J       Date:  1996-12       Impact factor: 2.401

5.  Deoxyribonucleic acid triplex formation inhibits granulocyte macrophage colony-stimulating factor gene expression and suppresses growth in juvenile myelomonocytic leukemic cells.

Authors:  M Kochetkova; P O Iversen; A F Lopez; M F Shannon
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

6.  Chronic granulocytic leukemia in children.

Authors:  G Garewal; R K Marwaha; N Marwaha; R Sarode; D Prakash
Journal:  Indian J Pediatr       Date:  1987 May-Jun       Impact factor: 1.967

Review 7.  Pediatric Neoplasms Presenting with Monocytosis.

Authors:  Jacob R Greenmyer; Mira Kohorst
Journal:  Curr Hematol Malig Rep       Date:  2021-02-25       Impact factor: 3.952

8.  Retroviral integration at the Epi1 locus cooperates with Nf1 gene loss in the progression to acute myeloid leukemia.

Authors:  S M Blaydes; S C Kogan; B T Truong; D J Gilbert; N A Jenkins; N G Copeland; D A Largaespada; C I Brannan
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

9.  Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.

Authors:  Hideki Muramatsu; Hideki Makishima; Anna M Jankowska; Heather Cazzolli; Christine O'Keefe; Nao Yoshida; Yinyan Xu; Nobuhiro Nishio; Asahito Hama; Hiroshi Yagasaki; Yoshiyuki Takahashi; Koji Kato; Atsushi Manabe; Seiji Kojima; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

10.  Prognostic factors in juvenile chronic granulocytic leukaemia.

Authors:  G Owen; I J Lewis; M Morgan; A Robinson; R F Stevens
Journal:  Br J Cancer Suppl       Date:  1992-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.